Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history

Thomas W. McDade; Alexis R. Demonbreun; Amelia Sancilio; Brian Mustanski; Richard T. D’Aquila; Elizabeth M. McNally

doi:10.1038/s41598-021-96879-3

Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history

Thomas W. McDade^*, Alexis R. Demonbreun, Amelia Sancilio, Brian Mustanski, Richard T. D’Aquila, Elizabeth M. McNally

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.

Original language	English (US)
Article number	17325
Journal	Scientific reports
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41598-021-96879-3
State	Published - Dec 2021

Funding

Financial support for this research from the National Science Foundation (BCS-2035114), National Institutes of Health (3UL1TR001422-06S4), and the Northwestern University Office of Research is gratefully acknowledged. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.

ASJC Scopus subject areas

General

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41598-021-96879-3

Cite this

@article{68937ad41c17458bac662896c74e5870,

title = "Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history",

abstract = "Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.",

author = "McDade, {Thomas W.} and Demonbreun, {Alexis R.} and Amelia Sancilio and Brian Mustanski and D{\textquoteright}Aquila, {Richard T.} and McNally, {Elizabeth M.}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1038/s41598-021-96879-3",

language = "English (US)",

volume = "11",

journal = "Scientific reports",

issn = "2045-2322",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history

AU - McDade, Thomas W.

AU - Demonbreun, Alexis R.

AU - Sancilio, Amelia

AU - Mustanski, Brian

AU - D’Aquila, Richard T.

AU - McNally, Elizabeth M.

PY - 2021/12

Y1 - 2021/12

N2 - Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.

AB - Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.

UR - http://www.scopus.com/inward/record.url?scp=85113867543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113867543&partnerID=8YFLogxK

U2 - 10.1038/s41598-021-96879-3

DO - 10.1038/s41598-021-96879-3

M3 - Article

C2 - 34462501

AN - SCOPUS:85113867543

SN - 2045-2322

VL - 11

JO - Scientific reports

JF - Scientific reports

IS - 1

M1 - 17325

ER -

Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this